Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Adverse Drug Reactions Journal ; 22(3):176-179, 2020.
Article in Chinese | EMBASE | ID: covidwho-2295935
Emerging Markets Finance and Trade ; 2023.
Article in English | Scopus | ID: covidwho-2286269


This paper examines the volatility spillover between the soybean futures contracts traded in the US Chicago Board of Trade (CBOT) and China Dalian Commodity Exchange (DCE) through a normalized Copula–GARCH(1,1) - t model with structural changes. The structural change points are identified through a combination of Bayesian diagnosis with Z-test. The study finds that the volatility spillover exists between the DCE and CBOT soybean futures and weakens through time. We further identify seven structural change points in the volatility spillover relationship, suggesting it is going through significant structural changes. The changes are related to major social-political events including the trade conflict between China and the US, the COVID-19 pandemic and the Russia-Ukraine war. © 2023 Taylor & Francis Group, LLC.

Eur Rev Med Pharmacol Sci ; 26(15): 5574-5580, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1988904


OBJECTIVE: The COVID-19 pandemic has influenced regular medical procedures and health-seeking behaviors. In this study, we aimed to investigate the influence of the COVID-19 pandemic on the presentation and prognosis of acute ischemic stroke (AIS) patients in county-level stroke centers. PATIENTS AND METHODS: We retrospectively collected AIS patients during the strict lockdown period (January 24, 2020, to March 27, 2020) and the corresponding "new normal" period (2021) of the COVID-19 pandemic. Patients seen during the same timeframe in 2019 were enrolled as controls. Statistical analysis was conducted to compare the clinical characteristics of AIS patients who presented during the lockdown and new normal periods and those who presented during the pre-COVID-19 pandemic period. RESULTS: A total of 134 AIS patients presented during the lockdown period (the 2020 group), 207 patients in the pre-COVID-19 period (the 2019 group) and 201 patients in the "new normal" period (the 2021 group). Compared to the 2019 group, there was approximately 1/3 reduction in the number of patients who presented during the lockdown period, while the number of patients who received IVT or EVT was similar between the two groups. The number of patients, baseline characteristics, workflow intervals and clinical outcomes presented during the "new normal" period were similar between the 2019 and 2021 groups. Logistic regression showed that lockdown or new normal status were not risk factors associated with a poor outcome at 90 days. CONCLUSIONS: In county-level city stroke centers, the COVID-19 lockdown resulted in a reduction in the number of patients with AIS admitted to the hospital but had no effect on patients treated with IVT or EVT. Lockdown or new normal status did not influence the prognosis of AIS patients.

COVID-19 , Ischemic Stroke , Stroke , COVID-19/epidemiology , Communicable Disease Control , Humans , Ischemic Stroke/diagnosis , Ischemic Stroke/epidemiology , Pandemics , Prognosis , Retrospective Studies , Stroke/epidemiology , Stroke/therapy
7th IEEE International Conference on Network Intelligence and Digital Content, IC-NIDC 2021 ; : 133-137, 2021.
Article in English | Scopus | ID: covidwho-1699527


Coronavirus disease of 2019 (COVID-19) is still severe nowadays, and plentiful COVID-19 patients need careful rehabilitation. The 6-minute walking test (6MWT) is a common clinical trial that requires the patient to walk as far as possible in a corridor for 6 minutes, significantly indicating patients' cardiopulmonary disease conditions and rehabilitation. A traditional 6MWT provides the 6-minute walking distance (6MWD) as the primary result for clinical analysis. In this paper, we propose Physio6, a sensor-based monitoring system for 6MWT, which monitors one patient's various physiological signals and indicates her/his condition during the test. The system also provides the functions of early warning based on physiological signal monitoring and automatically or manually recording the adverse events, such as hypoxia or dyspnea. Moreover, Physio6 is able to communicate with the existing systems in hospitals, and to generate a comprehensive report that summarizes the performance of the patient in the current 6MWT and even in the past ones. Our system has been deployed in four hospitals. Compared with the conventional distance-based measurement, our preliminary validation reveals that the extracted physiological parameters are promisingly valuable for clinical decision-making. System quality and device comfort are also confirmed by questionnaires. The potential of leveraging this system to perform the remote 6MWT at home/in communities as a solution of COVID-19 patient rehabilitation monitoring is also discussed. © 2021 IEEE.